

A placebo-controlled trial of captopril in refractory chro

Journal of the American College of Cardiology
2, 755-763

DOI: 10.1016/s0735-1097(83)80316-7

Citation Report

#	ARTICLE	IF	CITATIONS
1	Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism. <i>Journal of the American College of Cardiology</i> , 1983, 2, 841-852.	1.2	133
2	Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. <i>Circulation</i> , 1984, 70, 271-278.	1.6	285
3	Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. <i>Circulation</i> , 1984, 70, 63-68.	1.6	149
4	Captopril in heart failure. A double blind controlled trial. <i>Heart</i> , 1984, 52, 530-535.	1.2	351
5	Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. <i>Journal of the American College of Cardiology</i> , 1984, 3, 1035-1043.	1.2	117
6	Current concepts in the treatment of congestive heart failure. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 147S-150S.	1.1	1
7	Angiotensin converting enzyme inhibition in heart failure. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 157S-160S.	1.1	9
8	Efficacy of captopril in low-renin congestive heart failure: Importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders. <i>American Journal of Cardiology</i> , 1984, 54, 771-777.	0.7	35
9	Clinical applications of angiotensin-converting enzyme inhibitors. <i>American Journal of Medicine</i> , 1984, 77, 690-698.	0.6	47
10	Hemodynamic and regional blood flow response to captopril in congestive heart failure. <i>American Journal of Medicine</i> , 1984, 76, 38-42.	0.6	32
11	Conceptual dilemmas in the classification of vasodilator drugs for severe chronic heart failure. <i>American Journal of Medicine</i> , 1984, 76, 3-13.	0.6	26
12	Long-term captopril therapy for chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1984, 53, 1316-1320.	0.7	32
13	Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure. <i>American Journal of Cardiology</i> , 1984, 54, 596-599.	0.7	274
14	Caution: digitalis may be injurious to post-infarction patients. <i>International Journal of Cardiology</i> , 1984, 6, 95-98.	0.8	6
15	Hemodynamic Results of Perorally Administered Converting Enzyme Inhibitors in Congestive Heart Failure. <i>Scandinavian Journal of Urology and Nephrology</i> , 1984, 18, 129-132.	1.4	2
16	Chronic Congestive Heart Failure—The Nature of the Problem and Its Management in 1984. <i>American Journal of the Medical Sciences</i> , 1984, 288, 178-192.	0.4	3
17	Unloading the Heart in Congestive Heart Failure. <i>American Journal of Medicine</i> , 1984, 77, 67-70.	0.6	13
18	Renin and angiotensin responses to posture and exercise in elderly patients with heart failure. <i>European Heart Journal</i> , 1984, 5, 9-11.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Pilot Study of the Effects of the Angiotensin-Converting Enzyme Inhibitor Captopril on Patients with Essential Hypertension. <i>Journal of Clinical Pharmacology</i> , 1984, 24, 343-350.	1.0	21
20	Treatment of chronic heart failure: a review of recent drug trials.. <i>BMJ: British Medical Journal</i> , 1985, 291, 993-996.	2.4	70
21	Effects of diltiazem on cardiac function and regional blood flow at rest and during exercise in a conscious rat preparation of chronic heart failure (myocardial infarction).. <i>Circulation</i> , 1985, 71, 1262-1270.	1.6	41
22	Angiotensin converting enzyme inhibition. <i>Postgraduate Medicine</i> , 1985, 78, 229-248.	0.9	13
23	STABILITY AND INTER-RELATIONSHIPS OF HORMONE, HAEMODYNAMIC AND ELECTROLYTE LEVELS IN HEART FAILURE IN MAN. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1985, 12, 145-154.	0.9	7
24	Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.. <i>Heart</i> , 1985, 54, 305-312.	1.2	262
25	Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril.. <i>Circulation</i> , 1985, 72, 406-412.	1.6	719
26	Controlled trial of enalapril in congestive cardiac failure.. <i>Heart</i> , 1985, 54, 405-414.	1.2	64
27	Drug treatment of heart failure.. <i>Heart</i> , 1985, 54, 234-242.	1.2	18
28	Vasodilator Therapy for Chronic Congestive Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 1985, 254, 3070.	3.8	10
29	Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.. <i>Circulation</i> , 1985, 71, 963-971.	1.6	209
30	Plasma free captopril concentrations during short and long term treatment with oral captopril for heart failure.. <i>Heart</i> , 1985, 54, 160-165.	1.2	19
31	Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients.. <i>Heart</i> , 1985, 54, 298-304.	1.2	39
32	Dose requirements and hemodynamic effects of transdermal nitroglycerin compared with placebo in patients with congestive heart failure.. <i>Circulation</i> , 1985, 71, 980-986.	1.6	54
33	Influence of chronic captopril therapy on the infarcted left ventricle of the rat.. <i>Circulation Research</i> , 1985, 57, 84-95.	2.0	812
34	Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril.. <i>Heart</i> , 1985, 53, 431-435.	1.2	27
35	Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic. <i>International Journal of Cardiology</i> , 1985, 7, 111-120.	0.8	30
36	Effects of Enalapril on Clinical Status, Biochemistry, Exercise Performance and Haemodynamics in Heart Failure. <i>Drugs</i> , 1985, 30, 74-81.	4.9	17

#	ARTICLE	IF	CITATIONS
37	Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure. <i>Journal of the American College of Cardiology</i> , 1985, 5, 101-107.	1.2	141
38	Hemodynamic and clinical significance of the pulmonary vascular response to long-term captopril therapy in patients with severe chronic heart failure. <i>Journal of the American College of Cardiology</i> , 1985, 6, 635-645.	1.2	29
39	Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. <i>Journal of the American College of Cardiology</i> , 1985, 6, 163-170.	1.2	137
40	Is the renin-angiotensin system really unnecessary in patients with severe chronic heart failure: The price we pay for interfering with evolution. <i>Journal of the American College of Cardiology</i> , 1985, 6, 171-173.	1.2	20
41	ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: PAST, PRESENT, AND BRIGHT FUTURE. <i>Lancet, The</i> , 1985, 325, 30-34.	6.3	169
43	Effects of cardiac medications on ventricular performance: Emphasis on evaluation with radionuclide angiography. <i>American Heart Journal</i> , 1985, 109, 1070-1084.	1.2	11
44	Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: Results of a randomized crossover study. <i>American Heart Journal</i> , 1985, 109, 1293-1299.	1.2	30
45	Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. <i>American Heart Journal</i> , 1985, 110, 807-813.	1.2	146
46	Effect of vasodilators on survival in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1985, 55, 1110-1113.	0.7	126
47	Neurohumoral mechanisms involved in congestive heart failure. <i>American Journal of Cardiology</i> , 1985, 55, A15-A21.	0.7	157
48	Role of vasodilators in the treatment of congestive heart failure. <i>American Journal of Cardiology</i> , 1985, 55, A32-A35.	0.7	39
49	Effect of enalapril on ventricular arrhythmias in congestive heart failure. <i>American Journal of Cardiology</i> , 1985, 56, 566-569.	0.7	190
50	Epidemiology of congestive heart failure. <i>American Journal of Cardiology</i> , 1985, 56, A2-A6.	0.7	34
51	Nitrates for congestive heart failure. <i>American Journal of Cardiology</i> , 1985, 56, A19-A23.	0.7	26
52	Methodologic problems in clinical trials in heart failure. <i>Journal of Chronic Diseases</i> , 1985, 38, 353-363.	1.3	45
53	Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure. <i>American Heart Journal</i> , 1986, 112, 121-129.	1.2	29
54	Congestive heart failure and arrhythmias: An overview. <i>American Journal of Cardiology</i> , 1986, 57, B34-B37.	0.7	41
55	Vasodilator therapy. <i>American Journal of Medicine</i> , 1986, 80, 54-58.	0.6	13

#	ARTICLE	IF	CITATIONS
56	Neurohumoral activation during exercise in congestive heart failure. American Journal of Medicine, 1986, 81, 623-629.	0.6	49
57	Angiotensin converting enzyme inhibitors in congestive heart failure: Overview in comparison of captopril and enalapril. American Journal of Medicine, 1986, 81, 36-39.	0.6	38
58	Survival of patients with severe congestive heart failure treated with oral milrinone. Journal of the American College of Cardiology, 1986, 7, 661-670.	1.2	214
59	Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. Journal of the American College of Cardiology, 1986, 7, 671-680.	1.2	46
60	Enalapril in congestive heart failure: acute and chronic invasive hemodynamic evaluation. International Journal of Cardiology, 1986, 11, 37-48.	0.8	21
61	Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. New England Journal of Medicine, 1986, 314, 1547-1552.	13.9	2,360
62	Editorial note Enalapril in congestive heart failure: acute and chronic invasive haemodynamic evaluation. International Journal of Cardiology, 1986, 11, 49-51.	0.8	0
63	Adverse Reactions with Angiotensin Converting Enzyme (ACE) Inhibitors. Medical Toxicology, 1986, 1, 122-141.	1.7	71
64	Adverse Effects Associated with the Newer Inotropic Agents. Medical Toxicology, 1986, 1, 335-342.	1.7	11
65	The Role of Vasodilator Therapy in the Treatment of Severe Chronic Heart Failure. Drugs, 1986, 32, 13-26.	4.9	10
66	The Treatment of Heart Failure. Drugs, 1986, 32, 538-568.	4.9	34
67	Captopril in a case of severe congestive heart failure and peripheral vascular disease. International Journal of Cardiology, 1986, 11, 127-131.	0.8	0
68	SYMPTOMATIC ASSESSMENT OF PATIENTS WITH HEART FAILURE: DOUBLE-BLIND COMPARISON OF INCREASING DOSES OF DIURETICS AND CAPTOPRIL IN MODERATE HEART FAILURE. Lancet, The, 1986, 328, 770-772.	6.3	78
69	Chronic afterload reduction in infants and children with primary myocardial disease. Journal of Pediatrics, 1986, 108, 530-534.	0.9	9
70	ENZYME REPLACEMENT IN NERVOUS TISSUE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR FUCOSIDOSIS IN DOGS. Lancet, The, 1986, 328, 772-774.	6.3	44
71	Effects of Acute Angiotensin Converting Enzyme Inhibition on Renal Blood Flow in Patients with Stable Congestive Heart Failure. American Journal of the Medical Sciences, 1986, 292, 123-127.	0.4	14
72	Congestive Heart Failure. Medical Clinics of North America, 1986, 70, 829-851.	1.1	1
73	COMBINED SPIRONOLACTONE AND CONVERTING ENZYME INHIBITOR THERAPY FOR REFRACTORY HEART FAILURE. Australian and New Zealand Journal of Medicine, 1986, 16, 61-63.	0.5	33

#	ARTICLE	IF	CITATIONS
74	The acute haemodynamic effects of quinapril, a new non-sulphydryl angiotensin converting enzyme inhibitor, in patients with severe congestive cardiac failure. <i>European Journal of Clinical Pharmacology</i> , 1986, 31, 9-14.	0.8	34
75	Indoramin in heart failure: Possible adverse effects on hemodynamics and exercise capacity. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 40, 567-574.	2.3	2
76	Effect of captopril on the cerebral circulation in chronic heart failure. <i>European Journal of Clinical Investigation</i> , 1986, 16, 124-132.	1.7	48
77	Congestive heart failure. <i>Current Problems in Cardiology</i> , 1986, 11, 301-365.	1.1	3
78	Comparison of Captopril and Enalapril in Patients with Severe Chronic Heart Failure. <i>New England Journal of Medicine</i> , 1986, 315, 847-853.	13.9	302
79	Is inotropic therapy appropriate for patients with chronic congestive heart failure? Or is the digitalis leaf withering?. <i>Postgraduate Medical Journal</i> , 1986, 62, 585-592.	0.9	2
80	New Positive Inotropic Agents in the Treatment of Congestive Heart Failure. <i>New England Journal of Medicine</i> , 1986, 314, 290-299.	13.9	343
81	Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy.. <i>Heart</i> , 1986, 55, 391-399.	1.2	107
82	Vasodilator therapy of dilated cardiomyopathy.. <i>Postgraduate Medical Journal</i> , 1986, 62, 599-600.	0.9	4
83	Acute and Short-Term Effects of Clonidine in Heart Failure. <i>Angiology</i> , 1987, 38, 537-548.	0.8	31
84	Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects.. <i>Heart</i> , 1987, 58, 122-128.	1.2	60
85	Enalapril for Congestive Heart Failure. <i>New England Journal of Medicine</i> , 1987, 317, 1349-1351.	13.9	17
86	Combined Therapy with Dobutamine and Amrinone in Severe Heart Failure. <i>Chest</i> , 1987, 92, 657-662.	0.4	69
87	Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress.. <i>Heart</i> , 1987, 58, 505-511.	1.2	24
88	Factors influencing survival and mode of death in severe chronic ischaemic cardiac failure.. <i>Heart</i> , 1987, 57, 125-132.	1.2	44
89	Inhibition of Angiotensin-Converting Enzyme in Congestive Heart Failure. <i>New England Journal of Medicine</i> , 1987, 316, 879-880.	13.9	20
90	Clinical Response to Angiotensin-Converting Enzyme Inhibition in Cardiac Failure. <i>Clinical and Experimental Hypertension</i> , 1987, 9, 521-529.	0.3	0
91	Enalapril: A Long-Acting Angiotensin-Converting Enzyme Inhibitor. <i>Pharmacotherapy</i> , 1987, 7, 133-145.	1.2	7

#	ARTICLE	IF	CITATIONS
93	The Use of Angiotensin Converting Enzyme Inhibitors in Elderly Patients with Hypertension. Journal of the American Geriatrics Society, 1987, 35, 269-270.	1.3	10
94	Captopril versus placebo in congestive heart failure: effects on oxygen delivery to exercising skeletal muscle. European Heart Journal, 1987, 8, 1295-1304.	1.0	11
95	Vasodilators, diuretics and digitalis in cardiomegaly. European Heart Journal, 1987, 8, 255-256.	1.0	0
96	Potentially Deleterious Effects of Long-term Vasodilator Therapy in Patients with Heart Failure. Chest, 1987, 91, 737-744.	0.4	0
97	Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. Journal of the American College of Cardiology, 1987, 10, 837-844.	1.2	84
98	Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term captopril therapy in heart failure. Journal of the American College of Cardiology, 1987, 10, 845-850.	1.2	95
99	Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: Rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure. Journal of the American College of Cardiology, 1987, 9, 1131-1138.	1.2	65
100	How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. Journal of the American College of Cardiology, 1987, 9, 433-438.	1.2	97
101	BLOOD AND PROTEIN LOSS VIA SMALL-INTESTINAL INFLAMMATION INDUCED BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS. Lancet, The, 1987, 330, 711-714.	6.3	194
102	Long term use of enalapril in the treatment of patients with congestive heart failure. International Journal of Cardiology, 1987, 16, 137-144.	0.8	6
103	DOUBLE-BLIND COMPARISON OF CAPTOPRIL ALONE AGAINST FRUSEMIDE PLUS AMILORIDE IN MILD HEART FAILURE. Lancet, The, 1987, 330, 709-711.	6.3	159
104	A multicenter study of a new inotropic agent, piperanometozine (opc-8212) in congestive heart failure: Clinical improvement during short-term treatment. Cardiovascular Drugs and Therapy, 1987, 1, 169-175.	1.3	12
105	Angiotensin inhibitors and other vasodilators with special reference to congestive heart failure. Cardiovascular Drugs and Therapy, 1987, 1, 1-8.	1.3	9
106	Selective updates on mechanisms of action of positive inotropic agents. Molecular and Cellular Biochemistry, 1987, 76, 97-112.	1.4	21
107	Effect of captopril on left ventricular end-diastolic pressure, volume and stress-shortening relations in severe cardiac failure. Clinical Cardiology, 1987, 10, 340-344.	0.7	1
108	Dilated cardiomyopathy and myocarditis: Natural history, etiology, clinical manifestations, and management. Current Problems in Cardiology, 1987, 12, 574-647.	1.1	38
109	Acute hemodynamic, hormonal and electrolyte effects of ramipril in severe congestive heart failure. American Journal of Cardiology, 1987, 59, D155-D163.	0.7	17
110	Hemodynamic effects of PN 200-110 (isradipine) in congestive heart failure. American Journal of Cardiology, 1987, 59, B70-B74.	0.7	32

#	ARTICLE	IF	CITATIONS
111	Hemodynamic correlates of left ventricular versus right ventricular radionuclide volumetric responses to vasodilator therapy in congestive heart failure secondary to ischemic or dilated cardiomyopathy. American Journal of Cardiology, 1987, 59, 1131-1137.	0.7	13
112	Renal and circulatory mechanisms in congestive heart failure. Kidney International, 1987, 31, 1402-1415.	2.6	120
113	Skeletal muscle blood flow, metabolism and morphology in chronic congestive heart failure and effects of short- and long-term angiotensin-converting enzyme inhibition. American Journal of Cardiology, 1988, 62, 82E-85E.	0.7	8
114	Effect of drug therapy on survival in chronic congestive heart failure. American Journal of Cardiology, 1988, 62, 41A-45A.	0.7	49
115	Tolerability of enalapril in congestive heart failure. American Journal of Cardiology, 1988, 62, 67A-72A.	0.7	38
116	When and how to use angiotensin-converting enzyme inhibition in congestive heart failure. American Journal of Cardiology, 1988, 62, 75A-80A.	0.7	8
117	Therapeutic advances in heart failure. Cardiovascular Drugs and Therapy, 1988, 2, 413-418.	1.3	2
118	Measurement of the quality of life in congestive heart failure—Influence of drug therapy. Cardiovascular Drugs and Therapy, 1988, 2, 419-424.	1.3	19
119	A randomized cross-over study of enalapril in congestive heart failure: Haemodynamic and hormonal effects during rest and exercise. European Journal of Clinical Pharmacology, 1988, 34, 323-331.	0.8	10
120	Renal artery stenosis in heart failure. American Journal of Cardiology, 1988, 62, 1307-1308.	0.7	17
121	Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure. American Heart Journal, 1988, 116, 771-777.	1.2	32
122	Modulation of hemodynamic effects with a converting enzyme inhibitor: Acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. American Heart Journal, 1988, 116, 480-488.	1.2	35
123	Angiotensin converting enzyme inhibitors. II. Clinical use. American Heart Journal, 1988, 116, 1591-1605.	1.2	43
124	Current therapy for heart failure. American Journal of Medicine, 1988, 84, 51-55.	0.6	3
125	Isradipine improves cardiac function in congestive heart failure. American Journal of Medicine, 1988, 84, 56-61.	0.6	6
126	Converting enzyme inhibition and heart failure. American Journal of Medicine, 1988, 84, 87-91.	0.6	16
127	Lisinopril and captopril in the treatment of heart failure in older patients. American Journal of Medicine, 1988, 85, 44-47.	0.6	13
128	Lisinopril versus placebo in older congestive heart failure patients. American Journal of Medicine, 1988, 85, 48-54.	0.6	14

#	ARTICLE	IF	CITATIONS
129	New trends in the use of angiotensin converting enzyme inhibitors in chronic heart failure. American Journal of Medicine, 1988, 84, 36-46.	0.6	7
130	New trends in the use of angiotensin converting enzyme inhibitors in chronic heart failure. American Journal of Medicine, 1988, 84, 36-46.	0.6	1
131	Congestive heart failure. Disease-a-Month, 1988, 34, 469-536.	0.4	11
132	Digitalis. New England Journal of Medicine, 1988, 318, 358-365.	13.9	324
133	Captopril. Drugs, 1988, 36, 540-600.	4.9	193
134	Foreword. Journal of the American College of Cardiology, 1988, 12, 262-264.	1.2	5
135	I. Introduction. Journal of the American College of Cardiology, 1988, 12, 265-267.	1.2	23
136	I. Introduction. Journal of the American College of Cardiology, 1988, 12, 547-550.	1.2	24
137	III. Antagonist's viewpoint. Journal of the American College of Cardiology, 1988, 12, 554-558.	1.2	7
138	Vasodilator and inotropic drugs for the treatment of chronic heart failure: Distinguishing hype from hope. Journal of the American College of Cardiology, 1988, 12, 1299-1317.	1.2	118
139	Abnormalities of skeletal muscle in patients with chronic heart failure. International Journal of Cardiology, 1988, 18, 187-195.	0.8	359
140	Synergistic effect of captopril and dobutamine on left ventricular pressure-volume and pressure-shortening relations in severe cardiac failure. International Journal of Cardiology, 1988, 21, 157-166.	0.8	0
141	HUMAN IMMUNODEFICIENCY VIRUS DETECTED IN BOWEL EPITHELIUM FROM PATIENTS WITH GASTROINTESTINAL SYMPTOMS. Lancet, The, 1988, 331, 259-262.	6.3	392
142	TREATMENT OF PATIENTS WITH SYMPTOMLESS LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION. Lancet, The, 1988, 331, 255-259.	6.3	434
143	Comparative Effects of Therapy With Captopril and Digoxin in Patients With Mild to Moderate Heart Failure. JAMA - Journal of the American Medical Association, 1988, 259, 539.	3.8	500
144	Relative Efficacy of Vasodilator Therapy in Chronic Congestive Heart Failure. JAMA - Journal of the American Medical Association, 1988, 259, 3422.	3.8	35
145	Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure. European Heart Journal, 1988, 9, 105-108.	1.0	8
146	The Acute Effect of an Oral Inotropic Placebo on the Exercise Capacity of Patients with Chronic Cardiac Failure. Chest, 1988, 94, 262-266.	0.4	4

#	ARTICLE	IF	CITATIONS
147	Effect of Captopril on Progressive Ventricular Dilatation after Anterior Myocardial Infarction. New England Journal of Medicine, 1988, 319, 80-86.	13.9	1,117
148	The place of ACE inhibitors in the current treatment of chronic heart failure. Postgraduate Medical Journal, 1988, 64, 653-655.	0.9	1
149	Current therapy of the failing heart.. Circulation, 1988, 78, 1099-1107.	1.6	107
150	Large conduit arteries in hypertension: role of the vascular renin-angiotensin system.. Circulation, 1988, 77, 947-954.	1.6	219
151	Reduced lymphocyte stimulatory guanine nucleotide regulatory protein and beta-adrenergic receptors in congestive heart failure and reversal with angiotensin converting enzyme inhibitor therapy.. Circulation, 1988, 78, 1373-1379.	1.6	97
152	Angiotensin-Converting Enzyme Inhibition in Mild to Moderate Congestive Heart Failure: An Evolving Approach. American Journal of Hypertension, 1988, 1, 402S-409S.	1.0	2
153	Diagnostic Heterogeneity in Clinical Trials for Congestive Heart Failure. Annals of Internal Medicine, 1988, 109, 55.	2.0	64
154	Resting and exertional haemodynamic effects of buccalnitroglycerin: Acute and chronic discontinuous treatment in post-myocardial infarction patients with heart failure. European Heart Journal, 1988, 9, 252-258.	1.0	2
155	Converting enzyme inhibitors in heart failure. European Heart Journal, 1988, 9, 77-83.	1.0	8
156	Southwestern Internal Medicine Conference: The Multifaceted Role of Angiotensin Converting Enzyme Inhibitors in Congestive Heart Failure. American Journal of the Medical Sciences, 1988, 296, 275-288.	0.4	0
157	Modern treatment of heart failure.. BMJ: British Medical Journal, 1988, 297, 83-84.	2.4	10
158	Angiotensin-Converting Enzyme Inhibitors. Medical Clinics of North America, 1988, 72, 399-425.	1.1	34
159	Management of Congestive Heart Failure in the Elderly. Drug Intelligence & Clinical Pharmacy, 1988, 22, 788-792.	0.4	2
160	Clinical Trials in Congestive Heart Failure: Why Do Studies Report Conflicting Results?. Annals of Internal Medicine, 1988, 109, 3.	2.0	11
161	Personal view Congestive heart failure: how to evaluate efficacy of treatment. European Heart Journal, 1988, 9, 602-609.	1.0	3
162	Captopril and the diuretic requirements in moderate and severe chronic heart failure. European Heart Journal, 1989, 10, 586-690.	1.0	25
163	Medical Therapy for Chronic Congestive Heart Failure. Annals of Internal Medicine, 1989, 110, 758.	2.0	5
164	Therapeutic options in the management of chronic heart failure. Is there a drug of first choice?. Circulation, 1989, 79, 198-204.	1.6	52

#	ARTICLE	IF	CITATIONS
165	Effects of enalapril on myocardial noradrenaline overflow during exercise in patients with chronic heart failure.. Heart, 1989, 61, 23-28.	1.2	16
166	Unloading the Failing Heart: Previous Experience and Future Directions. American Journal of Hypertension, 1989, 2, 736-739.	1.0	6
167	Renal Hemodynamic Consequences of Angiotensin-Converting Enzyme Inhibition in Congestive Heart Failure. Archives of Internal Medicine, 1989, 149, 669.	4.3	40
168	Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial.. Circulation, 1989, 79, 491-502.	1.6	232
169	Captopril restores hemodynamic responsiveness to atrial natriuretic peptide in rats with heart failure.. Circulation, 1989, 80, 1886-1892.	1.6	30
170	Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine.. Circulation Research, 1989, 64, 330-337.	2.0	169
171	Therapeutic achievements of phosphodiesterase inhibitors and the future. European Heart Journal, 1989, 10, 53-59.	1.0	0
172	Development and testing of a new measure of health status for clinical trials in heart failure. Journal of General Internal Medicine, 1989, 4, 101-107.	1.3	316
173	Lisinopril for severe congestive heart failure. American Journal of Cardiology, 1989, 63, D8-D11.	0.7	3
174	Long-term effects of a once-a-day versus twice-a-day regimen of enalapril for congestive heart failure. American Journal of Cardiology, 1989, 63, D17-D21.	0.7	16
175	Comparison of enalapril versus digoxin for congestive heart failure. American Journal of Cardiology, 1989, 63, D22-D25.	0.7	35
176	Enalapril for congestive heart failure. American Journal of Cardiology, 1989, 63, D26-D32.	0.7	14
177	Relation between plasma norepinephrine and response to medical therapy in men with congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1989, 64, 609-613.	0.7	34
178	Vasodilator therapy without converting-enzyme inhibition in congestive heart failureâ€”Usefulness and limitations. Cardiovascular Drugs and Therapy, 1989, 3, 375-396.	1.3	7
179	Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses. Cardiovascular Drugs and Therapy, 1989, 3, 417-425.	1.3	10
180	The captopril-digoxin multicenter research group study on the comparative steps of captopril and digoxin in patients with mild/moderate heart failure: Implications for therapy. Cardiovascular Drugs and Therapy, 1989, 3, 7-9.	1.3	1
181	Low-dose enalapril in severe chronic heart failure. Cardiovascular Drugs and Therapy, 1989, 3, 211-218.	1.3	8
182	THERAPEUTIC PROGRESSâ€”REVIEW XXXIV: CONGESTIVE CARDIAC FAILURE. Journal of Clinical Pharmacy and Therapeutics, 1989, 14, 1-19.	0.7	2

#	ARTICLE	IF	CITATIONS
183	Adjusting for baseline: Change or percentage change?. <i>Statistics in Medicine</i> , 1989, 8, 1183-1190.	0.8	125
184	Clinical Perspectives on Positive Inotropic Therapy for Chronic Congestive Heart Failure. <i>Cardiovascular Drug Reviews</i> , 1989, 7, 301-309.	4.4	0
185	A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 312-320.	2.3	19
186	Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study. <i>International Journal of Cardiology</i> , 1989, 24, 311-316.	0.8	12
187	Mild heart failure: Diagnosis and treatment. <i>American Heart Journal</i> , 1989, 118, 1277-1291.	1.2	11
188	The evolution of antihypertensive therapy: An overview of four decades of experience. <i>Journal of the American College of Cardiology</i> , 1989, 14, 1595-1608.	1.2	30
189	Short- and long-acting angiotensin-converting enzyme inhibitors: A randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. <i>Journal of the American College of Cardiology</i> , 1989, 13, 1240-1247.	1.2	126
190	Angiotensin-converting enzyme inhibitors: Are there significant clinical differences?. <i>Journal of the American College of Cardiology</i> , 1989, 13, 1248-1250.	1.2	14
191	Determinants of exercise capacity in hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 1989, 13, 1521-1526.	1.2	65
192	Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. <i>Journal of the American College of Cardiology</i> , 1989, 13, 134-142.	1.2	151
193	Effects of left ventricular shape and captopril therapy on exercise capacity after anterior wall acute myocardial infarction. <i>American Journal of Cardiology</i> , 1989, 63, 1167-1173.	0.7	172
194	Comparison of the immediate and long-term effects of captopril and isosorbide dinitrate as adjunctive treatment in mild heart failure. <i>British Journal of Clinical Pharmacology</i> , 1989, 28, 427-434.	1.1	6
195	Clinical implications for therapy: possible cardioprotective effects of ACE inhibition. <i>British Journal of Clinical Pharmacology</i> , 1989, 28, 183S-187S.	1.1	13
196	The clinical significance of nitrate tolerance in patients with chronic heart failure. <i>European Heart Journal</i> , 1989, 10, 20-25.	1.0	12
197	Angiotensin-converting Enzyme Inhibitors in Heart Failure. <i>Medical Clinics of North America</i> , 1989, 73, 315-338.	1.1	12
198	Adherence and its management in clinical trials: Implications for arthritis treatment trials. <i>Arthritis and Rheumatism</i> , 1989, 2, A48-A57.	6.7	11
199	Treatment of Congestive Heart Failure with Angiotensin-Converting Enzyme Inhibitors. <i>Journal of Pharmacy Technology</i> , 1989, 5, 146-152.	0.5	1
200	ACE inhibitors. <i>Postgraduate Medicine</i> , 1990, 87, 223-243.	0.9	6

#	ARTICLE	IF	CITATIONS
201	Preventive treatment of asymptomatic left ventricular dysfunction following myocardial infarction. <i>European Heart Journal</i> , 1990, 11, 147-156.	1.0	41
202	The effect of ACE inhibition on myocardial energy metabolism. <i>European Heart Journal</i> , 1990, 11, 116-122.	1.0	30
203	Long-term Therapy with Benazepril in Patients with Congestive Heart Failure: Effects on Clinical Status and Exercise Tolerance. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 1106-1111.	1.0	10
204	Chronic Therapy for Congestive Heart Failure with Benazepril HCl, a New Angiotensin Converting Enzyme Inhibitor. <i>American Journal of the Medical Sciences</i> , 1990, 300, 354-360.	0.4	4
205	Exercise capacity and quality of life in the treatment of heart failure. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 48, 325-332.	2.3	41
206	Tissue renin-angiotensin systems in the heart and vasculature: Possible involvement in the cardiovascular actions of converting enzyme inhibitors. <i>American Journal of Cardiology</i> , 1990, 65, 3-10.	0.7	62
207	Neuroendocrine activation in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1990, 65, 32-34.	0.7	10
208	Mechanisms in heart failure and the role of angiotensin-converting enzyme inhibition. <i>American Journal of Cardiology</i> , 1990, 66, D2-D6.	0.7	13
209	Vasodilators have not been shown to be of value in all patients with chronic congestive heart failure due to left ventricular systolic dysfunction. <i>American Journal of Cardiology</i> , 1990, 66, 435-438.	0.7	6
210	Nitrates are effective in the treatment of chronic congestive heart failure: The protagonist's view. <i>American Journal of Cardiology</i> , 1990, 66, 444-446.	0.7	7
211	Studies of Left Ventricular Dysfunction (SOLVD) – Rationale, design and methods: Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. <i>American Journal of Cardiology</i> , 1990, 66, 315-322.	0.7	196
212	Effect on the myocardial energy metabolism of angiotensin-converting enzyme inhibition in chronic heart failure. <i>American Journal of Cardiology</i> , 1990, 65, 74-81.	0.7	67
213	Effects of captopril versus milrinone therapy in modulating the adrenergic nervous system response to exercise in congestive heart failure. <i>American Journal of Cardiology</i> , 1990, 65, 644-649.	0.7	25
214	Captopril improves hemodynamic response to static exercise in patients with congestive heart failure: A double-blind, placebo-controlled, randomized trial. <i>Clinical Cardiology</i> , 1990, 13, 329-334.	0.7	6
215	Cardiac effects of angiotensin converting enzyme inhibitors. <i>Cardiovascular Drugs and Therapy</i> , 1990, 4, 243-245.	1.3	3
216	Identification and Management of Potential Heart Transplant Recipients. <i>Cardiology Clinics</i> , 1990, 8, 11-21.	0.9	6
217	Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs captopril in patients with heart failure: a randomized double-blind study. <i>European Heart Journal</i> , 1990, 11, 712-721.	1.0	16
218	Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure. <i>Archives of Internal Medicine</i> , 1990, 150, 1798.	4.3	31

#	ARTICLE	IF	CITATIONS
219	Angiotensin converting enzyme inhibition and its impact on cardiovascular disease.. Circulation, 1990, 81, 381-388.	1.6	39
220	Endocrinologic Warfare: The Role of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure. Journal of Pharmacy Practice, 1990, 3, 318-331.	0.5	0
221	A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.. Circulation, 1990, 82, 1954-1961.	1.6	337
222	Quinapril in Chronic Heart Failure. American Journal of Hypertension, 1990, 3, 283S-287S.	1.0	2
223	Mechanism of Action of Angiotensin-Converting Enzyme (ACE) Inhibitors in Hypertension and Heart Failure. Drugs, 1990, 39, 11-16.	4.9	32
224	Early Intervention in Heart Failure. Drugs, 1990, 39, 4-9.	4.9	5
225	Drug Treatment of Heart Failure. Drugs, 1990, 39, 25-28.	4.9	0
226	Xamoterol in severe heart failure. Lancet, The, 1990, 336, 517-518.	6.3	82
227	Angiotensin-Converting Enzyme Inhibitors: A Comparative Review. DICP: the Annals of Pharmacotherapy, 1990, 24, 506-525.	0.2	38
228	Renal artery stenosis and peripheral vascular disease: implications for ACE inhibitor therapy. Lancet, The, 1990, 336, 321.	6.3	54
229	Sublingual administration of captopril versus nitroglycerin in patients with severe congestive heart failure. International Journal of Cardiology, 1990, 27, 351-359.	0.8	25
230	Enalapril as initial and sole treatment in severe chronic heart failure with sodium retention. International Journal of Cardiology, 1990, 28, 341-346.	0.8	24
231	Marked spontaneous improvement in ejection fraction in patients with congestive heart failure. American Journal of Medicine, 1990, 89, 303-307.	0.6	38
232	Regional blood flow supply and demand in heart failure. American Heart Journal, 1990, 120, 1547-1551.	1.2	30
233	Medical management of chronic heart failure: Inotropic, vasodilator, or inodilator drugs?. American Heart Journal, 1990, 120, 1558-1564.	1.2	5
234	The placebo effect in heart failure. American Heart Journal, 1990, 120, 1579-1582.	1.2	37
235	Effect of Captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. Journal of the American College of Cardiology, 1991, 17, 733-739.	1.2	92
236	Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine.. British Journal of Clinical Pharmacology, 1991, 31, 25-32.	1.1	8

#	ARTICLE	IF	CITATIONS
237	Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. <i>Lancet, The</i> , 1991, 337, 872-876.	6.3	307
238	Digoxin or Angiotensin Converting Enzyme Inhibitors for Congestive Heart Failure in Geriatric Patients. <i>Drugs and Aging</i> , 1991, 1, 98-103.	1.3	53
239	Cilazapril in Congestive Heart Failure. <i>Drugs</i> , 1991, 41, 54-61.	4.9	8
240	Cardiovascular Therapies in the 1990s. <i>Drugs</i> , 1991, 41, 345-357.	4.9	4
241	Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.. <i>Heart</i> , 1991, 66, 206-211.	1.2	86
242	Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. <i>New England Journal of Medicine</i> , 1991, 325, 293-302.	13.9	6,773
243	Oral enoximone therapy in chronic heart failure: A placebo-controlled randomized trial. <i>American Heart Journal</i> , 1991, 121, 1471-1479.	1.2	49
244	Future directions in vasodilator therapy for heart failure. <i>American Heart Journal</i> , 1991, 121, 969-974.	1.2	7
245	Coronary vasodilatation and improved myocardial lactate metabolism after angiotensin converting enzyme inhibition with cilazapril in patients with congestive heart failure. <i>American Heart Journal</i> , 1991, 122, 1382-1388.	1.2	33
246	Flosequinan: A vasodilator with positive inotropic activity. <i>American Heart Journal</i> , 1991, 121, 537-540.	1.2	28
247	Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: Long-term effectiveness of add-on therapy with pimobendan. <i>American Heart Journal</i> , 1991, 122, 517-522.	1.2	11
248	Acute heart failure: determinants of outcome. <i>International Journal of Cardiology</i> , 1991, 32, 365-375.	0.8	18
249	A Comparison of Enalapril with Hydralazineâ€“Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure. <i>New England Journal of Medicine</i> , 1991, 325, 303-310.	13.9	2,710
250	Heart Failure in 1991. <i>Cardiology</i> , 1991, 78, 81-94.	0.6	8
251	Reduced exercise tolerance in chronic heart failure and its relationship to neurohumoral factors. <i>European Heart Journal</i> , 1991, 12, 21-28.	1.0	36
252	Progressive congestive heart failure. <i>Postgraduate Medicine</i> , 1991, 89, 102-107.	0.9	2
253	Effect of Drug Treatment on Quality of Life in Mild to Moderate Heart Failure. <i>Drug Safety</i> , 1991, 6, 241-246.	1.4	7
254	Risks and Benefits of the Treatment of Heart Failure Current Status. <i>Drug Safety</i> , 1991, 6, 277-284.	1.4	0

#	ARTICLE	IF	CITATIONS
255	Anesthetic Implications of the Renin-Angiotensin System and Angiotensin-Converting Enzyme Inhibitors. <i>Anesthesia and Analgesia</i> , 1991, 72, 667-683.	1.1	54
256	Hemodynamic Determinants of Exercise Capacity in Chronic Heart Failure. <i>Annals of Internal Medicine</i> , 1991, 115, 377-386.	2.0	124
257	Nonpeptide Angiotensin II Receptor Antagonists. <i>American Journal of Hypertension</i> , 1991, 4, 271S-272S.	1.0	8
258	Congestive Heart Failure in the Elderly. <i>Journal of the American Geriatrics Society</i> , 1991, 39, 810-825.	1.3	66
259	14C-isomazole disposition in man after oral administration. <i>Pharmaceutical Research</i> , 1991, 08, 1413-1417.	1.7	2
260	Adaptive changes in the periphery and their therapeutic consequences. <i>American Journal of Cardiology</i> , 1991, 67, 29-34.	0.7	29
261	Effects of captopril on contractility after myocardial infarction: Experimental observations. <i>American Journal of Cardiology</i> , 1991, 68, 26-34.	0.7	14
262	Initial blood pressure response to enalapril in hospitalized patients (studies of left ventricular) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	0.7	20
263	Angiotensin-converting inhibitors in patients with congestive heart failure: A class effect?. <i>American Journal of Cardiology</i> , 1991, 68, 106-108.	0.7	11
264	Patient evaluation for cardiac transplantation. <i>Progress in Cardiovascular Diseases</i> , 1991, 33, 219-228.	1.6	20
265	Sublingual Administration of Captopril in Patients with Acute Myocardial Ischemia. <i>Clinical Cardiology</i> , 1991, 14, 463-468.	0.7	9
266	A large-scale trial of captopril for mild to moderate heart failure in the primary care setting. <i>Clinical Cardiology</i> , 1991, 14, 676-682.	0.7	20
267	Angiotensin-converting enzyme inhibition and physical training in heart failure. <i>Journal of Internal Medicine</i> , 1991, 230, 407-413.	2.7	55
268	Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study.. <i>Heart</i> , 1991, 66, 199-205.	1.2	21
269	Current Role of Digitalis Therapy in Patients With Congestive Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 1991, 265, 2995.	3.8	17
270	Hemodynamic Effects of Direct Angiotensin II Blockade Compared to Converting Enzyme Inhibition in Rat Model of Heart Failure. <i>American Journal of Hypertension</i> , 1991, 4, 334S-340S.	1.0	96
271	Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster. Hemodynamic, morphological, and biochemical correlates.. <i>Circulation Research</i> , 1991, 68, 1302-1312.	2.0	63
272	Effect of Medical Therapy on Survival of Patients with Dilated Cardiomyopathy. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 1991, 21, 919-930.	0.5	5

#	ARTICLE	IF	CITATIONS
273	Evidence for or Against the Efficacy of Afterload Reducers for Management of Heart Failure in Dogs. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 1991, 21, 945-955.	0.5	4
274	Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy.. <i>Circulation</i> , 1991, 83, 523-527.	1.6	60
275	Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy.. <i>Circulation</i> , 1991, 84, 2426-2441.	1.6	231
276	Captopril in children with cardiomyopathy.. <i>Circulation</i> , 1991, 83, 707-708.	1.6	3
277	Critical Analysis of Methods for Assessing Regional Blood Flow and Their Reliability in Clinical Medicine. <i>Chest</i> , 1992, 101, 219S-222S.	0.4	10
278	Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions. <i>New England Journal of Medicine</i> , 1992, 327, 685-691.	13.9	3,420
279	Can We Alter Survival in Patients With Congestive Heart Failure?. <i>JAMA - Journal of the American Medical Association</i> , 1992, 267, 1956.	3.8	10
280	An overview of survival studies in patients with heart failure.. <i>Postgraduate Medical Journal</i> , 1992, 68, 606-610.	0.9	1
281	Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure.. <i>Circulation</i> , 1992, 86, 1800-1809.	1.6	36
282	Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.. <i>Circulation</i> , 1992, 86, 431-438.	1.6	502
283	Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial.. <i>Heart</i> , 1992, 67, 289-296.	1.2	107
284	Blood Flow and Skeletal Muscle in Patients with Heart Failure. <i>Chest</i> , 1992, 101, 330S-332S.	0.4	5
285	A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure. <i>European Heart Journal</i> , 1992, 13, 1092-1100.	1.0	9
286	Effects of Enalapril on Heart Failure in Hypertensive Patients With Diastolic Dysfunction. <i>American Journal of Hypertension</i> , 1992, 5, 480-483.	1.0	13
287	Effects of dual-chamber pacing with short atrioventricular delay in dilated cardiomyopathy. <i>Lancet</i> , The, 1992, 340, 1308-1312.	6.3	351
288	Angiotensin Converting Enzyme Inhibitors Versus Digoxin for the Treatment of Congestive Heart Failure. <i>Drugs</i> , 1992, 43, 637-650.	4.9	10
289	Effect of captopril on functional, physiological and biochemical outcome criteria in aged heart failure patients.. <i>British Journal of Clinical Pharmacology</i> , 1992, 33, 167-178.	1.1	8
290	Regulatory role of brain angiotensins in the control of physiological and behavioral responses. <i>Brain Research Reviews</i> , 1992, 17, 227-262.	9.1	263

#	ARTICLE	IF	CITATIONS
291	The influence of captopril on intrahospital mortality and duration of hospitalization in Nigerians with congestive heart failure. <i>International Journal of Cardiology</i> , 1992, 36, 341-343.	0.8	5
292	Vasodilator therapy and survival in chronic congestive heart failure. <i>Journal of the American College of Cardiology</i> , 1992, 19, 1360-1362.	1.2	4
293	Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. <i>Journal of the American College of Cardiology</i> , 1992, 20, 1549-1555.	1.2	237
294	Prognostic significance of Doppler-derived left ventricular diastolic filling variables in dilated cardiomyopathy. <i>American Heart Journal</i> , 1992, 124, 1524-1533.	1.2	97
295	β_2 -Adrenergic contractile reserve as a predictor of clinical outcome in patients with idiopathic dilated cardiomyopathy. <i>American Heart Journal</i> , 1992, 124, 679-685.	1.2	58
296	Contrasting patterns of arterial and venous dilatation after intravenous captopril in patients with chronic cardiac failure and their relationship to plasma angiotensin II concentrations. <i>American Heart Journal</i> , 1992, 124, 1270-1276.	1.2	5
297	Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. <i>American Heart Journal</i> , 1992, 124, 1017-1025.	1.2	852
298	A comparison of the effects of captopril and flosequinan in patients with severe heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1992, 6, 465-470.	1.3	5
299	Sudden Death in Patients With Congestive Heart Failure: Future Directions. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992, 15, 451-470.	0.5	16
300	Influence of mitral regurgitation on the response to captopril therapy for congestive heart failure caused by idiopathic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 1992, 69, 373-376.	0.7	36
301	Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1992, 70, 354-358.	0.7	26
302	Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril. <i>American Journal of Cardiology</i> , 1992, 70, 1310-1314.	0.7	51
303	Review of randomized trials of digoxin therapy in patients with chronic heart failure. <i>American Journal of Cardiology</i> , 1992, 69, 48-63.	0.7	54
304	Effect of angiotensin-converting enzyme inhibitors on the peripheral circulation in heart failure. <i>American Journal of Cardiology</i> , 1992, 70, 50-54.	0.7	29
305	Angiotensin-converting enzyme inhibitors, left ventricular dysfunction, and early heart failure. <i>American Journal of Cardiology</i> , 1992, 70, 55-61.	0.7	10
306	Comparison of the first-dose effect of captopril and lisinopril in heart failure. <i>American Journal of Cardiology</i> , 1992, 70, 137-139.	0.7	3
307	The effects of captopril on training in patients with ischemic heart disease. <i>Clinical Cardiology</i> , 1992, 15, 330-334.	0.7	2
308	Aging in the americas: Its impact on cardiovascular health. <i>Clinical Cardiology</i> , 1992, 15, 627-629.	0.7	1

#	ARTICLE	IF	CITATIONS
309	Postinfarct heart failure: Role of diuretic therapy. <i>Cardiovascular Drugs and Therapy</i> , 1993, 7, 863-867.	1.3	0
310	The management of heart failure: A matter of definition?. <i>Cardiovascular Drugs and Therapy</i> , 1993, 7, 661-669.	1.3	1
311	Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1993, 7, 103-110.	1.3	9
312	LETTERS TO THE EDITOR. <i>Journal of Internal Medicine</i> , 1993, 234, 339-343.	2.7	5
313	How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. <i>American Journal of Cardiology</i> , 1993, 71, C3-C11.	0.7	110
314	Nitrates versus angiotensin-converting enzyme inhibitors for congestive heart failure. <i>American Journal of Cardiology</i> , 1993, 72, C21-C26.	0.7	7
315	Acceptability of perindopril in mild-to-moderate chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1993, 71, E61-E68.	0.7	9
316	Changes in pulmonary hemodynamics predict benefits in exercise capacity after ACE inhibition in patients with mild to moderate congestive heart failure. <i>Clinical Cardiology</i> , 1993, 16, 607-612.	0.7	6
317	Spontaneous variability of ventricular function in patients with chronic heart failure. <i>American Journal of Medicine</i> , 1993, 95, 513-518.	0.6	6
318	Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. <i>American Heart Journal</i> , 1993, 126, 879-886.	1.2	32
319	Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. <i>American Heart Journal</i> , 1993, 126, 798-806.	1.2	34
320	Efficacy and safety of intravenous captopril in congestive heart failure. <i>Current Therapeutic Research</i> , 1993, 53, 167-176.	0.5	9
321	Sodium cromoglycate prophylaxis for angiotensin-converting enzyme inhibitor cough. <i>Lancet</i> , The, 1993, 341, 560.	6.3	8
322	Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors. <i>New England Journal of Medicine</i> , 1993, 329, 1-7.	13.9	853
323	Phosphodiesterase Inhibitors. <i>Drug Safety</i> , 1993, 9, 404-409.	1.4	6
324	Pharmacokinetic Drug Interactions with ACE Inhibitors. <i>Clinical Pharmacokinetics</i> , 1993, 25, 20-58.	1.6	62
325	Effects of ACE Inhibitors on Heart Failure in The Netherlands. <i>Pharmacoeconomics</i> , 1993, 3, 387-397.	1.7	37
326	Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. <i>Journal of the American College of Cardiology</i> , 1993, 21, 655-661.	1.2	217

#	ARTICLE	IF	CITATIONS
327	Heart failure in the 1990s: Evolutions of a major public health problem in cardiovascular medicine. <i>Journal of the American College of Cardiology</i> , 1993, 22, A3-A5.	1.2	144
328	Role of converting enzyme inhibitors in the treatment of heart failure. <i>Journal of the American College of Cardiology</i> , 1993, 22, A154-A157.	1.2	8
329	Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: A double-blind, placebo-controlled study of quinapril. <i>Journal of the American College of Cardiology</i> , 1993, 22, 1557-1563.	1.2	89
330	Sympathetic alterations after sodium restriction and short-term captopril administration. <i>Journal of the American College of Cardiology</i> , 1993, 21, 177-181.	1.2	18
331	Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 1993, 22, 65-72.	1.2	128
332	The effects of oral ibopamine in patients with mild heart failure – a double blind placebo controlled comparison to furosemide. <i>International Journal of Cardiology</i> , 1993, 40, 221-227.	0.8	52
333	A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure. <i>European Heart Journal</i> , 1993, 14, 403-409.	1.0	29
334	Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart.. <i>Circulation</i> , 1993, 88, 472-480.	1.6	101
335	Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).. <i>Circulation</i> , 1993, 88, 492-501.	1.6	97
336	Vasodilator Therapy for Congestive Heart Failure. <i>Archives of Internal Medicine</i> , 1993, 153, 445.	4.3	17
337	Angiotensin converting enzyme inhibitors in heart failure: how good are they?. <i>Heart</i> , 1993, 69, 373-375.	1.2	15
338	The effect of recent advances in pharmacologic management on the prognosis of dilated cardiomyopathy.. <i>Japanese Circulation Journal</i> , 1993, 57, 1038-1046.	1.0	4
339	Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages. <i>European Heart Journal</i> , 1993, 14, 273-278.	1.0	40
340	Lymphocyte beta adrenoceptor upregulation and improved cardiac response to adrenergic stimulation following converting enzyme inhibition in congestive heart failure. <i>European Heart Journal</i> , 1993, 14, 243-250.	1.0	18
341	Angiotensin II Receptor Blockade: An Innovative Approach to Cardiovascular Pharmacotherapy. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 1023-1038.	1.0	72
342	The role of calcium antagonists in the treatment of chronic heart failure. <i>European Heart Journal</i> , 1993, 14, 38-44.	1.0	46
343	Pharmacologic Treatment of Acute Congestive Heart Failure Resulting from Left Ventricular Systolic or Diastolic Dysfunction. <i>Critical Care Nursing Clinics of North America</i> , 1993, 5, 261-269.	0.4	0
344	Symptomatic Left Ventricular Aneurysm – Long-Term Survival in Medically Treated Patients. <i>Medical Principles and Practice</i> , 1994, 4, 147-153.	1.1	0

#	ARTICLE	IF	CITATIONS
345	Use of Angiotensin-Converting Enzyme Inhibitors in Heart Failure. <i>Journal of Pharmacy Technology</i> , 1994, 10, 156-163.	0.5	1
346	Role of Vasodilator Therapy in Congestive Heart Failure: Effects on Mortality. <i>Cardiology Clinics</i> , 1994, 12, 87-99.	0.9	0
347	Cardiomyoplasty. <i>Vascular Surgery</i> , 1994, 28, 481-488.	0.3	11
348	Cellular mechanisms of captopril-induced matrix remodeling in Syrian hamster cardiomyopathy.. <i>Circulation</i> , 1994, 90, 1334-1342.	1.6	32
349	Captopril Treatment of Chronic Heart Failure in the Very Old. <i>Journal of Gerontology</i> , 1994, 49, M148-M152.	2.0	21
350	Cardiac failure in an elderly population. <i>Reviews in Clinical Gerontology</i> , 1994, 4, 199-211.	0.5	0
351	Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure.. <i>Heart</i> , 1994, 72, 528-533.	1.2	57
352	Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition.. <i>Circulation</i> , 1994, 90, 2748-2756.	1.6	31
353	Angiotensin-converting enzyme in human skeletal muscle. A simple in vitro assay of activity in needle biopsy specimens. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1994, 54, 105-111.	0.6	58
354	Peripheral factors in the management of congestive heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 75-82.	1.3	7
355	Long-term evaluation of treatment for chronic heart failure: A 1 year comparative trial of flosequinan and captopril. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 829-836.	1.3	9
356	Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. <i>Neuroscience and Biobehavioral Reviews</i> , 1994, 18, 21-53.	2.9	248
357	Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 1994, 73, 881-886.	0.7	87
358	Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin system. <i>American Heart Journal</i> , 1994, 127, 1388-1401.	1.2	109
359	Expanding the paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibitors. <i>American Heart Journal</i> , 1994, 128, 997-1009.	1.2	26
360	Exercise Testing in Heart Failure. <i>Drugs</i> , 1994, 47, 14-24.	4.9	15
361	Vasodilators in Heart Failure. <i>Drugs</i> , 1994, 47, 47-58.	4.9	20
362	Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. <i>European Heart Journal</i> , 1994, 15, 1659-1665.	1.0	28

#	ARTICLE	IF	CITATIONS
364	Lisinopril Versus Placebo in the Treatment of Heart Failure: The Lisinopril Heart Failure Study Group. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 673-680.	1.0	17
365	Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. <i>European Heart Journal</i> , 1995, 16, 4-6.	1.0	54
366	Contractile state is the major determinant of functional outcome in patients with left ventricular dysfunction treated with enalapril. <i>European Heart Journal</i> , 1995, 16, 808-817.	1.0	3
367	Anti-adrenergic effects of angiotensin converting enzyme inhibitors. <i>European Heart Journal</i> , 1995, 16, 37-41.	1.0	22
368	ACE inhibitors in non-ischaemic heart failure: Results from the MEGA trials. <i>European Heart Journal</i> , 1995, 16, 133-136.	1.0	6
369	Improvement in cardiac myocyte function by biological effects of medical therapy: A new concept in the treatment of heart failure. <i>European Heart Journal</i> , 1995, 16, 20-31.	1.0	38
370	Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure. <i>American Journal of Cardiology</i> , 1995, 76, 1253-1258.	0.7	25
371	The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. <i>American Journal of Cardiology</i> , 1995, 76, 18D-23D.	0.7	49
372	Congestive heart failure in elderly patients: Controlled study of delapril versus captopril. <i>American Journal of Cardiology</i> , 1995, 75, 37F-43F.	0.7	5
373	?Escape? of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. <i>Cardiovascular Drugs and Therapy</i> , 1995, 9, 145-149.	1.3	189
374	Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: Results of a placebo-controlled trial. <i>Cardiovascular Drugs and Therapy</i> , 1995, 9, 589-594.	1.3	21
375	Czech and Slovak spirapril intervention study (CASSIS). <i>European Journal of Clinical Pharmacology</i> , 1995, 49, 95-102.	0.8	19
376	Effect of captopril on myocardial β -adrenoceptor density and Gi β -proteins in patients with mild to moderate heart failure due to dilated cardiomyopathy. <i>European Journal of Clinical Pharmacology</i> , 1995, 47, 389-94.	0.8	15
377	Exercise testing for patients with heart failure. <i>ACC Current Journal Review</i> , 1995, 4, 59-63.	0.1	1
378	Neuroendocrine changes in heart failure and their clinical relevance. <i>Clinical Cardiology</i> , 1995, 18, 440-445.	0.7	50
379	New Medical Therapies for Advanced Left Ventricular Dysfunction. <i>Cardiology Clinics</i> , 1995, 13, 27-34.	0.9	5
380	Effects of captopril and enalapril on renal function in elderly patients with chronic heart failure. <i>Postgraduate Medical Journal</i> , 1995, 71, 287-292.	0.9	9
381	Angiotensin II receptor antagonism: Losartan sites and mechanisms of action. <i>Clinical Therapeutics</i> , 1995, 17, 1005-1030.	1.1	17

#	ARTICLE	IF	CITATIONS
382	Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. <i>Regulatory Peptides</i> , 1995, 59, 269-295.	1.9	142
383	Effects of angiotensin II and angiotensin-converting enzyme inhibitors on human myocardium. <i>European Journal of Pharmacology</i> , 1995, 294, 17-27.	1.7	10
384	Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1995, 25, S47-S51.	1.2	9
385	Mortality as an endpoint for cardiac failure therapy. <i>Journal of Cardiac Failure</i> , 1995, 1, 191-194.	0.7	3
386	Effects of the Angiotensin Converting Enzyme Inhibitor Captopril on Experimental Autoimmune Encephalomyelitis. <i>Immunopharmacology and Immunotoxicology</i> , 1995, 17, 471-491.	1.1	59
387	Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. <i>Journal of Cardiac Failure</i> , 1996, 2, 47-54.	0.7	200
388	Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. <i>American Heart Journal</i> , 1996, 131, 177-185.	1.2	39
389	The Management of Chronic Heart Failure. <i>New England Journal of Medicine</i> , 1996, 335, 490-498.	13.9	309
390	Current Guidelines for the Treatment of Congestive Heart Failure. <i>Drugs</i> , 1996, 51, 89-98.	4.9	18
391	What is the ideal study design for evaluation of treatment for heart failure?: Insights from trials assessing the effect of ACE inhibitors on exercise capacity. <i>European Heart Journal</i> , 1996, 17, 120-134.	1.0	89
392	Beta-blockade in the management of chronic heart failure: Another step in the conceptual evolution of a neurohormonal model of the disease. <i>European Heart Journal</i> , 1996, 17, 21-23.	1.0	20
393	Evaluation of Angiotensin-Converting Enzyme Inhibitor in Congestive Heart Failure.. <i>Internal Medicine</i> , 1996, 35, 65-67.	0.3	0
394	Adaptive changes in the acute haemodynamic effects of cilazapril during chronic treatment. <i>European Journal of Clinical Pharmacology</i> , 1996, 50, 433-441.	0.8	9
395	Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. <i>American Journal of Cardiology</i> , 1996, 77, 832-838.	0.7	130
396	Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. <i>American Journal of Cardiology</i> , 1996, 77, 242-246.	0.7	50
397	Medical treatment of eng-stage heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1996, 10, 617-622.	1.3	2
398	Activation of the neuroendocrine response in heart failure: Adaptive or maladaptive process?. <i>Cardiovascular Drugs and Therapy</i> , 1996, 10, 623-629.	1.3	15
399	Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. <i>Molecular and Cellular Biochemistry</i> , 1996, 157, 251-8.	1.4	15

#	ARTICLE	IF	CITATIONS
400	Left Ventricular Dysfunction and Heart Failure Mechanistic and Therapeutic Distinctions. Clinical and Experimental Hypertension, 1996, 18, 559-568.	0.5	0
401	ACE inhibitors unmask incoordinate diastolic wall motion in restrictive left ventricular disease.. Heart, 1996, 76, 326-331.	1.2	41
402	EXPLAINING FATIGUE IN CONGESTIVE HEART FAILURE. Annual Review of Medicine, 1996, 47, 241-256.	5.0	104
403	Heart Failure Treatment With Angiotensin-Converting Enzyme Inhibitors in Hospitalized Medicare Patients in 10 Large States. Archives of Internal Medicine, 1997, 157, 1103.	4.3	86
404	Angiotensin-Converting Enzyme Inhibitor Up-Regulates Cardiac β -Receptors in Cultured Neonatal Rat Myocytes. Japanese Circulation Journal, 1997, 61, 170-179.	1.0	7
405	Efficacy of Monotherapy with Benazepril, an Angiotensin Converting Enzyme Inhibitor, in Dogs with Naturally Acquired Chronic Mitral Insufficiency.. Journal of Veterinary Medical Science, 1997, 59, 513-520.	0.3	36
406	An open, parallel group comparison of quinapril and captopril, when added to diuretic therapy, in the treatment of elderly patients with heart failure. Current Medical Research and Opinion, 1997, 13, 583-592.	0.9	6
407	The mysterious angiotensin converting enzyme inhibitors. Journal of Cardiac Failure, 1997, 3, 161-163.	0.7	2
408	Angiotensin-converting enzyme inhibitors in heart failure: Physicians' prescribing behavior. Journal of Cardiac Failure, 1997, 3, 295-302.	0.7	14
409	The Progression From Hypertension to Heart Failure. American Journal of Hypertension, 1997, 10, 280S-288S.	1.0	21
410	Stress-Induced Left Ventricular Outflow Tract Obstruction: A Potential Cause of Dyspnea in the Elderly. Journal of the American College of Cardiology, 1997, 30, 1301-1307.	1.2	79
411	References for health-related quality-of-life claims in prescription drug advertisements. American Journal of Health-System Pharmacy, 1997, 54, 2596-2599.	0.5	11
412	Overview of the Treatment of Heart Failure. American Journal of Cardiology, 1997, 80, 2L-6L.	0.7	23
413	Reverse remodeling in heart failure with intensification of vasodilator therapy. Clinical Cardiology, 1997, 20, 697-702.	0.7	38
414	Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril. Cardiovascular Drugs and Therapy, 1997, 11, 63-69.	1.3	10
415	Renal hemodynamic effects in patients with moderate to severe heart failure during chronic treatment with trandolapril. Cardiovascular Drugs and Therapy, 1998, 12, 395-403.	1.3	10
416	Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clinical Cardiology, 1998, 21, 103-108.	0.7	82
417	β -adrenergic blockade in chronic heart failure: Principles, progress, and practice. Progress in Cardiovascular Diseases, 1998, 41, 39-52.	1.6	99

#	ARTICLE	IF	CITATIONS
418	Effects of Spironolactone on Exercise Capacity and Neurohormonal Factors in Patients with Heart Failure Treated with Loop Diuretics and Angiotensin-Converting Enzyme Inhibitor. <i>General Pharmacology</i> , 1998, 31, 93-99.	0.7	19
419	15 years of heart-failure trials: what have we learned?. <i>Lancet, The</i> , 1998, 352, SI29-SI33.	6.3	49
420	β -Blockade in Heart Failure Basic Concepts and Clinical Results. <i>American Journal of Hypertension</i> , 1998, 11, 23S-37S.	1.0	35
421	Paradoxical hypertension after reversal of heart failure in patients treated with intensive vasodilator therapy. <i>American Journal of Hypertension</i> , 1998, 11, 1041-1047.	1.0	4
422	Improvement in the mechanical efficiency of walking: An explanation for the "placebo effect" seen during repeated exercise testing of patients with heart failure. <i>American Heart Journal</i> , 1998, 135, 107-114.	1.2	33
423	Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure. <i>Journal of Cardiac Failure</i> , 1998, 4, 115-119.	0.7	30
424	Mechanism of β^2 -Adrenergic Receptor Upregulation Induced by ACE Inhibition in Cultured Neonatal Rat Cardiac Myocytes. <i>Circulation</i> , 1998, 97, 2268-2273.	1.6	33
425	Pharmacologic Management of Chronic Heart Failure: A Review. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 1998, 2, 168-190.	0.4	2
426	Captopril Reduces the β -Adrenergic Receptor Upregulation Induced by ACE Inhibition in Cultured Neonatal Rat Cardiac Myocytes. <i>Circulation</i> , 1998, 97, 2268-2273.	0.4	9
427	Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. <i>European Heart Journal</i> , 1998, 19, 481-489.	1.0	167
428	QUANTIFICATION OF EXERCISE TOLERANCE IN CONGESTIVE HEART FAILURE AND ROLE OF ACE INHIBITORS. <i>Medical Journal Armed Forces India</i> , 1998, 54, 331-334.	0.3	0
429	North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. <i>BMJ: British Medical Journal</i> , 1998, 316, 1369-1375.	2.4	68
430	Exercise Tolerance as a Guide to Therapeutic Efficacy for Heart Failure. <i>Circulation</i> , 1999, 100, 2208-2209.	1.6	2
431	Classic techniques in medicine: The role of exercise testing in the evaluation and management of heart failure. <i>Postgraduate Medical Journal</i> , 1999, 75, 453-458.	0.9	11
432	ACE inhibitors and heart failure in hospital: any difference between cardiologists and general physicians?. <i>Postgraduate Medical Journal</i> , 1999, 75, 219-221.	0.9	23
433	Angiotensin-Converting Enzyme Inhibition Restores Hepatocyte Growth Factor Production in Patients With Congestive Heart Failure. <i>Hypertension</i> , 1999, 33, 1374-1378.	1.3	22
434	Comprehensive multidisciplinary programs for the management of patients with congestive heart failure. <i>Journal of General Internal Medicine</i> , 1999, 14, 130-135.	1.3	130
435	The Value of Questionnaires in Assessing Physical Activity, Fitness, and Quality of Life. <i>Heart Failure Reviews</i> , 1999, 3, 305-311.	1.7	3

#	ARTICLE	IF	CITATIONS
438	Symptomatic systolic ventricular failure. <i>Current Cardiology Reports</i> , 1999, 1, 20-28.	1.3	0
439	Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. <i>Progress in Cardiovascular Diseases</i> , 1999, 41, 265-300.	1.6	33
441	Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin converting enzyme inhibitor fosinopril in congestive heart failure. <i>Journal of Cardiac Failure</i> , 1999, 5, 17-24.	0.7	4
442	ARCTIC: Assessment of haemodynamic Response in patients with Congestive heart failure to Telmisartan: A multicentre dose-ranging study In Canada. <i>American Heart Journal</i> , 1999, 138, 843-848.	1.2	21
443	Prolonged Beneficial Effects of a Home-Based Intervention on Unplanned Readmissions and Mortality Among Patients With Congestive Heart Failure. <i>Archives of Internal Medicine</i> , 1999, 159, 257.	4.3	232
444	Pacing for heart failure: selection of patients, techniques and benefits. <i>European Journal of Heart Failure</i> , 1999, 1, 275-279.	2.9	22
445	Angiotensin-Converting Enzyme Inhibitor Use in Older Patients with Heart Failure and Renal Dysfunction. <i>Journal of the American Geriatrics Society</i> , 1999, 47, 302-308.	1.3	37
446	Effect of Beta-Blocker Therapy on Severe Ventricular Arrhythmias in Patients With Idiopathic Dilated Cardiomyopathy. <i>Japanese Circulation Journal</i> , 2000, 64, 87-92.	1.0	6
447	Plasma clearance of polyfructosan and extracellular body fluid distribution in idiopathic dilated cardiomyopathy and after heart transplantation. <i>American Journal of Cardiology</i> , 2000, 85, 843-848.	0.7	1
448	Underutilization and clinical benefits of angiotensin-converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. <i>American Journal of Cardiology</i> , 2000, 86, 644-648.	0.7	21
449	Effect of Heart Failure Program on Cardiovascular Drug Utilization and Dosage in Patients with Chronic Heart Failure. <i>Clinical Cardiology</i> , 2000, 23, 909-914.	0.7	25
450	The effects of neurohormonal antagonism on pathologic left ventricular remodeling in heart failure. <i>Current Cardiology Reports</i> , 2000, 2, 90-98.	1.3	3
451	Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. <i>European Journal of Heart Failure</i> , 2000, 2, 229-233.	2.9	30
452	Community pharmacist outreach program directed at physicians treating congestive heart failure. <i>American Journal of Health-System Pharmacy</i> , 2000, 57, 747-752.	0.5	13
453	Bradykinin Regulates Captopril-induced Upregulation of β_2 -Adrenergic Receptor in Cultured Neonatal Rat Cardiomyocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2000, 32, 153-159.	0.9	6
454	Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. <i>American Heart Journal</i> , 2000, 139, 503-510.	1.2	48
455	Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2000, 6, 3-10.	0.7	49
456	Low-dose enoximone improves exercise capacity in chronic heart failure—A list of the Enoximone Study Group Members and institutional affiliations is provided in the appendix. <i>Journal of the American College of Cardiology</i> , 2000, 36, 501-508.	1.2	58

#	ARTICLE	IF	CITATIONS
457	Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. <i>Journal of the American College of Cardiology</i> , 2000, 36, 2090-2095.	1.2	71
458	A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1757-1764.	1.2	71
459	Formulating clinical strategies for angiotensin antagonism: a review of preclinical and clinical studies. <i>American Journal of Medicine</i> , 2001, 110, 471-480.	0.6	12
460	Medical management of mild-to-moderate heart failure before the advent of beta blockers. <i>American Journal of Medicine</i> , 2001, 110, 47-62.	0.6	2
461	The role of gas analysis with exercise testing. <i>Primary Care - Clinics in Office Practice</i> , 2001, 28, 159-179.	0.7	7
463	The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure. <i>Archives of Internal Medicine</i> , 2001, 161, 667.	4.3	25
464	Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure. <i>Archives of Internal Medicine</i> , 2001, 161, 165.	4.3	76
465	Comparative Haemodynamic Responses to the First Dose of Short- and Long-acting ACE Inhibitors in Patients with Congestive Heart Failure. <i>Current Medical Research and Opinion</i> , 2001, 17, 290-297.	0.9	9
466	Dobutamine as bridge to angiotensin-converting enzyme inhibitor-nitrate therapy in endstage heart failure. <i>Clinical Cardiology</i> , 2001, 24, 231-236.	0.7	14
467	Treatment of Congestive Heart Failure. <i>Archives of Internal Medicine</i> , 2001, 161, 342.	4.3	65
468	Mediators of Chronic Heart Failure: How Drugs Work. <i>Annals of Pharmacotherapy</i> , 2001, 35, 1066-1074.	0.9	2
469	Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2002, 29, 1060-1065.	0.9	22
470	Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. <i>American Journal of Cardiology</i> , 2003, 91, 18-40.	0.7	108
471	Adverse Effects of ACE Inhibitors in Patients with Chronic Heart Failure and/or Ventricular Dysfunction. <i>Drug Safety</i> , 2003, 26, 895-908.	1.4	21
472	Evaluation of pulmonary hypertension in heart transplant candidates. <i>Current Opinion in Cardiology</i> , 2003, 18, 136-140.	0.8	25
473	Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, S16-S20.	0.5	21
474	Pharmacist interventions to improve the management of coronary artery disease. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 2672-2678.	0.5	18
477	A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction. <i>European Journal of Heart Failure</i> , 2004, 6, 927-935.	2.9	28

#	ARTICLE	IF	CITATIONS
478	Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. <i>Clinical Science</i> , 2004, 107, 539-557.	1.8	291
479	Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? â€” A systematic review. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2005, 6, 16.	1.5	28
480	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adultâ€”Summary Article. <i>Circulation</i> , 2005, 112, 1825-1852.	1.6	402
481	The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. <i>European Heart Journal</i> , 2005, 26, 145-152.	1.0	47
482	Dissociation Between Improvement in Left Ventricular Performance and Functional Class in Patients With Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 46, 262-268.	0.8	7
483	Tratamiento de la insuficiencia card�aca en fase muy avanzada. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2005, 12, 315-324.	0.0	0
484	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. <i>Circulation</i> , 2005, 112, e154-235.	1.6	2,179
485	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. <i>Journal of the American College of Cardiology</i> , 2005, 46, e1-e82.	1.2	1,860
486	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adultâ€”Summary Article. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1116-1143.	1.2	373
487	Medical Treatment of Patients with Heart Failure or Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 313-325.	1.0	1
488	Renin-Angiotensin System and Angiotensin Converting Enzyme Inhibitors in Chronic Heart Failure. , 0, , 30-43.		0
489	Pharmacological treatment of chronic heart failure. <i>Heart Failure Reviews</i> , 2006, 11, 109-123.	1.7	29
490	Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction-a meta-analysis. <i>European Journal of Heart Failure</i> , 2006, 8, 90-96.	2.9	24
491	Review: Imidapril in Heart Failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, 146-154.	1.0	3
493	Potential Mechanisms of Benefit with Thalidomide in Chronic Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 127-134.	1.0	5
494	Pharmacologic Therapy of Chronic Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 235-248.	1.0	22
495	Longâ€”term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2008, 10, 298-307.	2.9	47
496	ANGIOTENSIN II AND MYOCARDIAL INFARCTION. <i>Rational Pharmacotherapy in Cardiology</i> , 2008, 4, 105-110.	0.3	2

#	ARTICLE	IF	CITATIONS
497	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. <i>Circulation</i> , 2009, 119, e391-479.	1.6	2,001
498	2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. <i>Circulation</i> , 2009, 119, 1977-2016.	1.6	1,423
499	Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1439.	3.8	1,694
500	EFFECTS OF ACE INHIBITION ON REGIONAL CIRCULATION IN CONGESTIVE HEART FAILURE. <i>Acta Medica Scandinavica</i> , 1986, 219, 91-93.	0.0	4
501	End-of-life care in heart failure. <i>Current Cardiology Reports</i> , 2009, 11, 184-191.	1.3	27
502	ACE inhibitors in the treatment of heart failure. <i>Clinical Cardiology</i> , 2009, 13, VII-32-VII-38.	0.7	13
503	Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy. <i>Clinical Cardiology</i> , 2005, 28, 19-27.	0.7	7
504	2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1343-1382.	1.2	212
505	Palliative Care in Congestive Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 54, 386-396.	1.2	329
506	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. <i>Journal of the American College of Cardiology</i> , 2009, 53, e1-e90.	1.2	1,386
507	Pharmacologic Prevention of Anthracycline-Induced Cardiomyopathy. <i>Cardiology in Review</i> , 2009, 17, 243-252.	0.6	11
508	Heart failure therapy: beyond the guidelines. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 919-927.	0.6	7
510	Antihypertensive and organ-protective effects of benazepril. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1653-1671.	0.6	6
511	Substituted Benzimidazole Derivatives as Angiotensin II -AT1 Receptor Antagonist: A Review. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010, 10, 1366-1384.	1.1	40
512	Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2010, 56, 392-406.	1.2	387
513	Measurement of breathlessness in clinical trials in patients with chronic heart failure: the need for a standardized approach: a systematic review. <i>European Journal of Heart Failure</i> , 2010, 12, 137-147.	2.9	53
514	Epidemiology of Cardiorenal Syndrome. <i>Heart Failure Clinics</i> , 2010, 6, 333-346.	1.0	14
516	Chronic Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 153-171.	1.0	65

#	ARTICLE	IF	CITATIONS
517	Epidemiology of Cardiorenal Syndrome. <i>Cardiology Clinics</i> , 2011, 29, 301-314.	0.9	9
518	Novel targets for the treatment of heart failure: Perspectives from a heart failure clinician and trialist. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 51, 438-440.	0.9	7
519	ACE inhibitors in cardiac surgery: current studies and controversies. <i>Hypertension Research</i> , 2011, 34, 15-22.	1.5	16
520	Evaluating Research in Cardiovascular Medicine. <i>Circulation</i> , 2011, 123, 1038-1043.	1.6	10
521	Influence of cyclovirobuxine D on intracellular [Ca ²⁺] regulation and the expression of the calcium cycling proteins in rat myocytes. <i>FÅ-toterapÅ-Åç</i> , 2012, 83, 1653-1665.	1.1	12
522	Pulmonary Hypertension Associated with Left-Sided Heart Disease. <i>Heart Failure Clinics</i> , 2012, 8, 447-459.	1.0	27
523	Cost-effectiveness of heart failure therapies. <i>Nature Reviews Cardiology</i> , 2013, 10, 338-354.	6.1	66
524	The Effect of Coenzyme Q 10 on Morbidity and Mortality in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 641-649.	1.9	326
525	Appropriateness of Medications Prescribed to Elderly Patients with Advanced Heart Failure and Limited Life Expectancy Who Died During Hospitalization. <i>Drugs and Aging</i> , 2014, 31, 541-546.	1.3	15
526	The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. <i>Clinical Science</i> , 2015, 130, 57-77.	1.8	208
527	Reverse Remodeling in Systolic Heart Failure. <i>Cardiology in Review</i> , 2015, 23, 173-181.	0.6	26
528	Nursing concerns with palliative care and at the end-of-life in patients with heart failure. <i>Nursing (Auckland, N Z)</i> , 2015, , 33.	2.0	3
530	Palliative care issues in heart transplant candidates. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 5-13.	0.5	13
531	Clinical Characteristics and Treatment of Cardiomyopathies in Children. <i>Current Cardiology Reviews</i> , 2016, 12, 85-98.	0.6	15
532	Varying effects of recommended treatments for heart failure with reduced ejection fraction: meta-analysis of randomized controlled trials in the ESC and ACCF/AHA guidelines. <i>ESC Heart Failure</i> , 2016, 3, 235-244.	1.4	17
533	Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure. <i>Circulation</i> , 2016, 134, 1664-1678.	1.6	34
534	Palliative Care in Older Adults with Cardiovascular Disease: Addressing Misconceptions to Advance Care. <i>Current Cardiovascular Risk Reports</i> , 2017, 11, 1.	0.8	2
535	Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 399-407.	1.9	31

#	ARTICLE	IF	CITATIONS
536	Heart Failure with Myocardial Recovery - The Patient Whose Heart Failure Has Improved: What Next?. Progress in Cardiovascular Diseases, 2017, 60, 226-236.	1.6	24
537	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	47
538	Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target. Cardiovascular Pharmacology: Open Access, 2017, 06, .	0.1	7
539	Heart failure as a substrate and trigger for ventricular tachycardia. Journal of Interventional Cardiac Electrophysiology, 2019, 56, 229-247.	0.6	38
540	Congestive Heart Failure in Children. Pediatrics in Review, 2019, 40, 60-70.	0.2	19
541	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. Circulation Research, 2019, 124, 1520-1535.	2.0	115
542	Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management. Journal of Cardiology, 2020, 75, 233-241.	0.8	26
543	Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. , 2020, , 520-548.		0
544	A Modern Integration of Palliative Care Into the Management of Heart Failure. Canadian Journal of Cardiology, 2020, 36, 1050-1060.	0.8	11
545	Benefits and adverse effects of ACE inhibitors in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2021, 77, 321-329.	0.8	7
546	Comparative effectiveness of exercise training program in patients with heart failure: protocol for a systematic review of randomised controlled trials and network meta-analysis. BMJ Open, 2021, 11, e043160.	0.8	1
547	Updates in pharmacotherapy of heart failure with reduced ejection fraction. Annals of Translational Medicine, 2021, 9, 516-516.	0.7	5
548	Representation of Black patients in heart failure clinical trials. Current Opinion in Cardiology, 2021, 36, 329-334.	0.8	5
549	Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?. International Journal of Heart Failure, 2021, 3, 106.	0.9	3
551	Renal Salt and Water Handling in Congestive Heart Failure. , 1994, , 161-173.		2
552	The Medical Management of Chronic Congestive Heart Failure. , 1994, , 628-644.		3
553	Oxidative Damage in Chronic Heart Failure: Protection by Captopril Through Free Radical Scavenging?. Advances in Experimental Medicine and Biology, 1990, 264, 251-255.	0.8	5
554	The role of ACE inhibition in heart failure. , 2001, , 71-79.		4

#	ARTICLE	IF	CITATIONS
555	Pharmakologie und klinische Pharmakologie der AT1-Rezeptorantagonisten. , 1997, , 41-73.		1
557	Effect of Angiotensin-Converting Enzyme Inhibitors on Energy Metabolism in Chronic Heart Failure - Enzymatic Studies of Myocardial Biopsies. , 1988, , 485-493.		2
558	Converting Enzyme Inhibitors. Handbook of Experimental Pharmacology, 1990, , 377-481.	0.9	30
559	Endocrine Response to Heart Failure. Update in Intensive Care and Emergency Medicine, 1988, , 74-88.	0.6	1
560	The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatric Cardiology, 1993, 14, 9-12.	0.6	90
561	Blockade of the Renin-Angiotensin System: Effect on Mortality in Patients with Left Ventricular Systolic Dysfunction. Cardiology Clinics, 1994, 12, 101-114.	0.9	2
562	Progress in Angiotensin-Converting Enzyme Inhibition in Heart Failure: Rationale, Mechanisms, and Clinical Responses. Cardiology Clinics, 1989, 7, 119-130.	0.9	5
563	Comparative Immediate Hemodynamic and Hormonal Effects of Amrinone and Captopril in Patients with Severe Chronic Heart Failure. American Journal of the Medical Sciences, 1986, 291, 8-15.	0.4	6
564	Clinical Benefit of Angiotensin-Converting Enzyme Inhibitors in Chronic Heart Failure. Journal of Cardiovascular Pharmacology, 1996, 27, 19-24.	0.8	15
565	Circadian Variation in Blood Pressure and Heart Rate in Nonhypertensive Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 1996, 28, 733-740.	0.8	24
566	Angiotensin II-Receptor Blockade Further Reduces Afterload Safely in Patients Maximally Treated with Angiotensin-Converting Enzyme Inhibitors for Heart Failure. Journal of Cardiovascular Pharmacology, 1997, 30, 533-536.	0.8	51
567	Reduced Alveolar Capillary Membrane Diffusing Capacity in Chronic Heart Failure. Circulation, 1995, 91, 2769-2774.	1.6	202
568	Losartan in Heart Failure. Circulation, 1995, 91, 691-697.	1.6	246
569	Effects of Carvedilol, a Vasodilator β_1 -Blocker, in Patients With Congestive Heart Failure Due to Ischemic Heart Disease. Circulation, 1995, 92, 212-218.	1.6	204
570	Growth Hormone Improves Cardiac Performance in Experimental Heart Failure. Circulation, 1995, 92, 262-267.	1.6	198
571	Early Left Ventricular Dysfunction Elicits Activation of Sympathetic Drive and Attenuation of Parasympathetic Tone in the Paced Canine Model of Congestive Heart Failure. Circulation, 1995, 92, 555-561.	1.6	56
572	Thromboxane A ₂ Mediates the Stimulation of Inositol 1,4,5-Trisphosphate Production and Intracellular Calcium Mobilization by Bradykinin in Neonatal Rat Ventricular Cardiomyocytes. Hypertension, 1996, 28, 444-449.	1.3	26
573	HEART FAILURE AND FIRST DOSE HYPOTENSION AFTER ANGIOTENSIN CONVERTING ENZYME INHIBITORS. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2004, 148, 113-118.	0.2	1

#	ARTICLE	IF	CITATIONS
574	Akute kardiale Dyspnoe und LungenÄrdem. , 2000, , 527-538.		0
575	Pathophysiologie der chronischen Herzinsuffizienz. , 2000, , 545-595.		0
576	Klinik und Symptomatologie der chronischen Herzinsuffizienz. , 2000, , 597-610.		0
577	Definition und Epidemiologie der chronischen Herzinsuffizienz. , 2000, , 539-543.		0
578	Prognostic Indicators and Assessment of Therapeutic Responses. , 2002, , 145-159.		0
579	Angiotensin-converting Enzyme Inhibition and Angiotensin Receptor Blockade. , 2002, , 193-209.		0
580	Biventricular Pacing: How to Predict the Clinical Response in the Single Patient?. , 2002, , 646-653.		0
582	Inhibition of the Renin-Angiotensin-Aldosterone System. , 2005, , 195-212.		0
583	The Medical Management of Heart Failure. , 2007, , 1397-1416.		0
584	The heart failure patient. , 2007, , 451-464.		0
586	Antagonism of the Renin-Angiotensin-Aldosterone System in Heart Failure. , 2011, , 659-673.		0
587	Alterations in the Peripheral Circulation in Heart Failure. , 2011, , 279-290.		0
589	New Inotropic Agents. , 1985, , 305-320.		1
590	Primary and secondary prevention of coronary artery disease by drug therapy. , 1985, , 79-157.		0
591	Nitrate Therapy of Congestive Heart Failure. International BÄrhringer Mannheim Symposia, 1985, , 299-305.	0.5	2
592	Langzeittherapie der schweren chronischen Herzinsuffizienz mit Captopril: eine doppelblinde randomisierte plazebokontrollierte Langzeitstudie. , 1986, , 174-189.		0
593	Maximale Belastungstoleranz von Patienten mit kongestiver Herzinsuffizienz unter einer chronischen Therapie mit Captopril, Prazosin und unter Kombination beider Pharmaka. , 1986, , 190-200.		0
594	HÄmodynamik vor und sechs Monate nach Captopril bei Herzinsuffizienz. , 1986, , 167-173.		0

#	ARTICLE	IF	CITATIONS
595	Hemodynamic Consequences of Myocardial Infarction and the Role of Vasodilators in Acute and Chronic Management. , 1986, , 39-84.		0
596	Perspectives on the Use of New Phosphodiesterase Inhibitors in the Treatment of Chronic Cardiac Failure. Developments in Cardiovascular Medicine, 1987, , 193-209.	0.1	0
597	Are Placebo-Controlled Trials Necessary in the Evaluation of New Therapeutic Agents in Severe Chronic Heart Failure?. Developments in Cardiovascular Medicine, 1987, , 143-149.	0.1	0
598	Status of Vasodilators for Heart Failure. Developments in Cardiovascular Medicine, 1987, , 187-192.	0.1	0
600	Vasodilatoren bei schwerer Herzinsuffizienz. , 1988, , 65-79.		0
601	Dilated Cardiomyopathy: The Role of the Right Ventricle in Determining Functional Capacity. Developments in Cardiovascular Medicine, 1988, , 131-140.	0.1	0
603	Dilatative Kardiomyopathie. , 1989, , 9-69.		0
604	Treatment of Heart Failure by "Afterload" Reduction: Vasodilator or Angiotensin Converting Enzyme Inhibitor?. , 1990, , 66-75.		0
605	Vasodilator Therapy for Cardiomyopathy. , 1990, , 428-434.		0
606	Cardiac Transplantation for Dilated Cardiomyopathy. , 1990, , 462-469.		0
607	Management of Severe Heart Failure. Update in Intensive Care and Emergency Medicine, 1990, , 350-357.	0.6	0
608	Drugs for Heart Failure. , 1990, , 313-325.		0
609	Exercise Testing and Training of Patients with Congestive Heart Failure and Left Ventricular Dysfunction. , 1991, , 359-367.		0
610	Chronische Herzinsuffizienz. , 1991, , 607-690.		1
611	ACE-Hemmung als therapeutisches Prinzip. Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin, 1991, , 539-566.	0.0	0
612	Chronische Herzinsuffizienz einschlieÃlich Therapie mit Herzglykosiden. , 1991, , 80-98.		0
613	Hauptthema: Herzinsuffizienz. Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin, 1991, , 149-194.	0.0	0
614	Long-Term Double-Blind Comparative Study of Ibopamine Versus Placebo in the Treatment of Chronic Congestive Heart Failure. , 1991, , 219-230.		0

#	ARTICLE	IF	CITATIONS
615	ANGIOTENSIN CONVERTING ENZYME INHIBITOR IMPROVES CARDIAC HYPERTROPHY AND FAILURE IN A RAT MODEL OF MYOCARDIAL INFARCTION. The KITAKANTO Medical Journal, 1992, 42, 201-211.	0.0	0
617	Angiotensin-converting enzyme inhibitors in the treatment of clinical heart failure. , 1993, 88 Suppl 1, 203-209.		1
619	Angiotensin-Converting Enzyme Inhibitor Therapy for Congestive Heart Failure: Rationale, Results, and Current Recommendations. , 1994, , 380-399.		1
620	Gated blood-pool radionuclide ventriculography. Developments in Cardiovascular Medicine, 1994, , 145-157.	0.1	2
621	Kombinationstherapie von ACE-Hemmern mit positiv-inotropen Pharmaka. Aktuelle Therapieprinzipien in Kardiologie Und Angiologie, 1996, , 183-196.	0.1	0
622	Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. , 1996, , 251-258.		0
623	Klinischer Einsatz der ACE-Hemmer. Aktuelle Therapieprinzipien in Kardiologie Und Angiologie, 1996, , 123-165.	0.1	0
624	Comparison of Direct Angiotensin II Receptor Blockade with Converting Enzyme Inhibition in the Rat Model of Heart Failure. Progress in Experimental Cardiology, 1998, , 515-525.	0.0	0
625	Disorders of Potassium Metabolism. , 1998, , 53-83.		1
626	Pharmacological Interruption Of The Renin System And The Kidney: Lessons From Comparative Pharmacology. Progress in Experimental Cardiology, 1998, , 3-13.	0.0	0
627	Pharmakologie und klinische Pharmakologie der AT1-Rezeptorantagonisten. , 1999, , 39-75.		1
629	Inhibition of the Renin-Angiotensin-Aldosterone System. , 2017, , 85-96.		0
630	Management of Heart Failure. Annals of Saudi Medicine, 1984, 4, 363-369.	0.5	0
632	Cardiac resynchronisation therapy: do we know everything?. , 2006, , 257-266.		0
633	Recent Advances in the Management of Chronic Heart Failure. Primary Care - Clinics in Office Practice, 1985, 12, 117-142.	0.7	1
634	Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients. American Journal of Cardiovascular Disease, 2017, 7, 108-113.	0.5	55
635	Effects of Sacubitril/Valsartan Treatment on Left Ventricular Myocardial Torsion Mechanics in Patients with Heart Failure Reduced Ejection Fraction 2D Speckle Tracking Echocardiography. Journal of Cardiovascular Echography, 2021, 31, 59-67.	0.1	1
637	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008970.	1.6	8

#	ARTICLE	IF	CITATIONS
638	Standard Medical Therapy of Heart Failure. , 0, , 21-43.		0
639	Adequate enrollment of women in cardiovascular drug trials and the need for sex-specific assessment and reporting. American Heart Journal Plus, 2022, , 100155.	0.3	0
640	Renin Angiotensin System Inhibitors in Heart Failure with Reduced Ejection Fraction: Clinical Evidence and Considerations for Use. , 2023, , 331-347.		0
641	The First Dedicated Comprehensive Heart Failure Program in the United States: The Division of Circulatory Physiology at Columbia Presbyterian (1992â€“2004). Journal of Cardiac Failure, 2023, 29, 1078-1090.	0.7	0